Effect of glutamine in patients with esophagus resection.
Glutamine is the most abundant amino-acid in the extra- and intracellular compartments of the human body, which accounts for over 50% of its free amino-acid content. Utilization of glutamine peptides is explicitly useful, resulting in a decrease in the number of postoperative infectious complications, period of hospitalization, and therapeutic costs. This article aims to study the effects of glutamine on systemic inflammatory response, morbidity, and mortality after esophagectomy. A prospective, randomized, double-blind, and controlled trial was used. Following sealed-envelope block randomization, the patients were divided into two groups. Members of the glutamine group (group G) received glutamine (Dipeptiven, Fresenius) as continuous infusion for 6 hours at 0.5 g/kg for 3 days prior to, and 7 days following surgery; while patients of the control group were given placebo. We examined 30 patients in group G, and 25 patients as controls. In both patient groups, the levels of total protein, albumin, pre-albumin, retinol binding protein, transferrin, transferring-saturation, C-reactive protein, procalcitonin, lymphocte, Interleukin-6, Interleukin-8, tumor necrosis factor alpha, and serum lactate were determined prior to surgery (t(0)), directly after surgery (t(u)), following surgery on day 1 (t(1)), day 2 (t(2)), and day 7 (t(7)). For statistical analysis Mann-Whitney U test and chi-square test were used. There was no significant difference between the two groups regarding age, male/female ratio, and SAPS II scores. Intensive care unit morbidity and mortality was similar in both groups (group G: 24 survivors/6 nonsurvivors;


METHODS
17 survivors/8 nonsurvivors; P= 0.607). Daily Multiple Organ Dysfunction Score did not differ significantly between the two groups. The observed inflammatory markers followed the pattern we described without significant difference. Based on our study, the glutamine supplementation that we used had no influence on morbidity, mortality, or postoperative inflammatory response after esophagectomy.
Marton
S
S
Department of Anaesthesiology and Intensive Therapy, University of Pecs, 7643 Pecs, Hungary. smarton11@hotmail.com
Ghosh
S
S
Papp
A
A
Bogar
L
L
Koszegi
T
T
Juhasz
V
V
Cseke
L
L
Horvath
P O
PO
D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide; D004311:Double-Blind Method; D016629:Esophagectomy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005973:Glutamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D019344:Lactic Acid / Q000097:blood; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011183:Postoperative Complications / Q000517:prevention & control*; D011228:Prealbumin / Q000032:analysis; D011292:Premedication; D011446:Prospective Studies; D011498:Protein Precursors / Q000097:blood; D012177:Retinol-Binding Proteins / Q000032:analysis; D012709:Serum Albumin / Q000032:analysis; D015996:Survival Rate; D018746:Systemic Inflammatory Response Syndrome / Q000517:prevention & control*; D014168:Transferrin / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D001798:Blood Proteins; C000606589:CALCA protein, human; D006023:Glycoproteins; D015850:Interleukin-6; D016209:Interleukin-8; D010919:Placebos; D011228:Prealbumin; D011498:Protein Precursors; D012177:Retinol-Binding Proteins; D012709:Serum Albumin; D014168:Transferrin; D014409:Tumor Necrosis Factor-alpha; D005973:Glutamine; D019344:Lactic Acid; D002116:Calcitonin; D002097:C-Reactive Protein; D015740:Calcitonin Gene-Related Peptide